FOLD

Company Overview — What Does AMICUS THERAPEUTICS, INC. Do?

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. AMICUS THERAPEUTICS, INC. (FOLD) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Bradley L. Campbell and employs approximately 480 people, headquartered in CRANBURY, New Jersey. With a market capitalization of $4.5B, FOLD is one of the notable companies in the Healthcare sector.

AMICUS THERAPEUTICS, INC. (FOLD) Stock Rating — Hold (April 2026)

As of April 2026, AMICUS THERAPEUTICS, INC. receives a Hold rating with a composite score of 44.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.FOLD ranks #747 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AMICUS THERAPEUTICS, INC. ranks #53 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

FOLD Stock Price and 52-Week Range

AMICUS THERAPEUTICS, INC. (FOLD) currently trades at $14.46. The stock lost $0.01 (0.0%) in the most recent trading session. The 52-week high for FOLD is $14.39, which means the stock is currently trading 0.5% from its annual peak. The 52-week low is $5.51, putting the stock 162.5% above its annual trough. Recent trading volume was 894K shares, suggesting relatively thin trading activity.

Is FOLD Overvalued or Undervalued? — Valuation Analysis

AMICUS THERAPEUTICS, INC. (FOLD) carries a value factor score of 39/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 35.09x, compared to the Healthcare sector average of 23.63x — a premium of 48%. The price-to-book ratio stands at 16.57x, versus the sector average of 2.75x. The price-to-sales ratio is 7.69x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, FOLD trades at 128.21x EV/EBITDA, versus 6.34x for the sector.

At current multiples, AMICUS THERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AMICUS THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

AMICUS THERAPEUTICS, INC. (FOLD) earns a quality factor score of 43/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -13.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.7% versus the sector average of -33.1%.

On a margin basis, AMICUS THERAPEUTICS, INC. reports gross margins of 90.0%, compared to 71.5% for the sector. The operating margin is 5.8% (sector: -66.1%). Net profit margin stands at -6.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 33.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

FOLD Debt, Balance Sheet, and Financial Health

AMICUS THERAPEUTICS, INC. has a debt-to-equity ratio of 143.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.84x, indicating strong short-term liquidity. Total debt on the balance sheet is $393M. Cash and equivalents stand at $191M.

FOLD has a beta of 0.72, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for AMICUS THERAPEUTICS, INC. is 66/100, reflecting average volatility within the normal range for its sector.

AMICUS THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AMICUS THERAPEUTICS, INC. reported revenue of $591M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-36M. Gross margin was 90.0%. Operating income came in at $39M.

In FY 2025, AMICUS THERAPEUTICS, INC. reported revenue of $634M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-27M. Gross margin was 88.5%. Revenue grew 20.0% year-over-year compared to FY 2024. Operating income came in at $33M.

In Q3 2025, AMICUS THERAPEUTICS, INC. reported revenue of $169M and earnings per share (EPS) of $0.06. Net income for the quarter was $17M. Gross margin was 88.5%. Revenue grew 19.5% year-over-year compared to Q3 2024. Operating income came in at $34M.

In Q2 2025, AMICUS THERAPEUTICS, INC. reported revenue of $155M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-24M. Gross margin was 90.2%. Revenue grew 22.1% year-over-year compared to Q2 2024. Operating income came in at $-9M.

Over the past 8 quarters, AMICUS THERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $127M to $591M. Investors analyzing FOLD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

FOLD Dividend Yield and Income Analysis

AMICUS THERAPEUTICS, INC. (FOLD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

FOLD Momentum and Technical Analysis Profile

AMICUS THERAPEUTICS, INC. (FOLD) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 10/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

FOLD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AMICUS THERAPEUTICS, INC. (FOLD) ranks #53 out of 838 stocks based on the Blank Capital composite score. This places FOLD in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing FOLD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full FOLD vs S&P 500 (SPY) comparison to assess how AMICUS THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

FOLD Next Earnings Date

No upcoming earnings date has been announced for AMICUS THERAPEUTICS, INC. (FOLD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy FOLD? — Investment Thesis Summary

AMICUS THERAPEUTICS, INC. presents a balanced picture with arguments on both sides. The value score of 39/100 indicates premium valuation. Price momentum is positive at 65/100, suggesting the trend favors buyers. Low volatility (stability score 66/100) reduces downside risk.

In summary, AMICUS THERAPEUTICS, INC. (FOLD) earns a Hold rating with a composite score of 44.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on FOLD stock.

Related Resources for FOLD Investors

Explore more research and tools: FOLD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare FOLD head-to-head with peers: FOLD vs AZN, FOLD vs SLGL, FOLD vs VMD.